Bottom line
PPH vs FHLC: the short answer
PPH (VanEck Pharmaceutical ETF) and FHLC (Fidelity MSCI Health Care Index ETF) share a meaningful slice of their top holdings — about 42% by weight.
But FHLC is far broader, holding 337 positions to 26 for PPH, so beyond the top names it adds exposure PPH doesn't have.
FHLC is cheaper at 0.084% vs 0.36% — a difference of $28 a year per $10,000 invested.
Over five years, PPH returned +11.3% a year vs +7.2% for FHLC (reporting dates differ).
Updated Nov 19, 2026
PPH vs FHLC side by side
| PPH | FHLC | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | VanEck | Fidelity |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.36% | 0.084% |
| Annual cost per $10k | $36 | $8.4 |
| 10-yr cost on $10k (prospectus) | $456 | $108 |
| Max front load | None | None |
| 12b-1 fee | — | 0% |
| 1-yr return | +21.9% | +2.6% |
| 5-yr return (annualized) | +11.3% | +7.2% |
| 10-yr return (annualized) | +6.7% | +8.8% |
| Best quarter | +16.5% | +16.4% |
| Worst quarter | −15.0% | −13.1% |
| Net assets (fund) | $879.5M | $3.3B |
| Number of holdings | 26 | 337 |
| Portfolio turnover | 3% | 3% |
| Returns as of | Dec 31, 2025 | Nov 30, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PPH | FHLC | Difference |
|---|---|---|---|
| 2024 | +8.1% | +2.6% | +5.5% |
| 2023 | +6.9% | +2.5% | +4.4% |
| 2022 | +2.6% | −5.5% | +8.1% |
| 2021 | +18.3% | +20.4% | −2.1% |
| 2020 | +5.2% | +18.1% | −12.9% |
| 2019 | +19.1% | +21.9% | −2.8% |
| 2018 | −5.7% | +5.5% | −11.2% |
| 2017 | +15.4% | +23.3% | −7.9% |
| 2016 | −17.8% | −3.3% | −14.4% |
Source: Fund prospectus bar charts
Holdings overlap
8 of PPH's top 25 holdings also appear in FHLC's top 25.
| Holding | PPH | FHLC |
|---|---|---|
| Eli Lilly & Co | 20.23% | 13.35% |
| Merck & Co Inc | 9.85% | 4.66% |
| AbbVie Inc | 4.57% | 6.42% |
| Pfizer Inc | 4.51% | 2.06% |
| Bristol-Myers Squibb Co | 4.47% | 1.93% |
| Johnson & Johnson | 4.35% | 8.93% |
| McKesson Corp | 4.12% | 1.52% |
| Cencora Inc | 3.36% | 0.83% |
Source: SEC Form N-PORT
PPH top 10
- Eli Lilly & Co — 20.23%
- Novartis AG — 10.63%
- Merck & Co Inc — 9.85%
- Novo Nordisk A/S — 5.37%
- AbbVie Inc — 4.57%
- Pfizer Inc — 4.51%
- Bristol-Myers Squibb Co — 4.47%
- Gsk Plc — 4.42%
- Johnson & Johnson — 4.35%
- AstraZeneca PLC — 4.33%
FHLC top 10
- Eli Lilly & Co — 13.35%
- Johnson & Johnson — 8.93%
- AbbVie Inc — 6.42%
- UnitedHealth Group Inc — 5.44%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 3.09%
- Amgen Inc — 3.00%
- Abbott Laboratories — 2.66%
- Gilead Sciences Inc — 2.34%
- Pfizer Inc — 2.06%
FAQ
What is the difference between PPH and FHLC?
Which is cheaper, PPH or FHLC?
Should I own both PPH and FHLC?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.